,file,ref_number,ref_text,doi,doi_url
0,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[1],"Ohgaki H, Kleihues P. 2009. Clinical Neuropathology. Genetic pathways to primary and secondary glioblastoma.",10.2353/ajpath.2007.070011,https://doi.org/10.2353/ajpath.2007.070011
1,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[2],"Samuels Y, et al. 2004. Science. High frequency of mutations of the PIK3CA gene in human cancers.",10.3410/f.1004498.210508,https://doi.org/10.3410/f.1004498.210508
2,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[3],"Hegi ME, et al. 2005. New England Journal of Medicine. MGMT gene silencing and benefit from temozolomide in glioblastoma.",10.1056/nejmoa043331,https://doi.org/10.1056/nejmoa043331
3,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[4],"Stupp R, et al. 2005. New England Journal of Medicine. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.",10.1097/01.cot.0000289242.47980.f9,https://doi.org/10.1097/01.cot.0000289242.47980.f9
4,experiments/glioblastoma_survival/ai_messages/high_complexity--generated_TP53_PIK3CA_MGMT_medium_methylated,[5],"Janku F, et al. 2018. Nature Reviews Clinical Oncology. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.",10.1200/jco.2011.36.1196,https://doi.org/10.1200/jco.2011.36.1196
